An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. (Q53536563)

15 May 2018

title

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. (English)

1 reference

15 May 2018

0 references

1 reference

8

Targan SR

1 reference

15 May 2018

author name string

Vasiliauskas EA

1

1 reference

15 May 2018

Kam LY

2

1 reference

15 May 2018

Abreu-Martin MT

3

1 reference

15 May 2018

Hassard PV

4

1 reference

15 May 2018

Papadakis KA

5

1 reference

15 May 2018

Yang H

6

1 reference

15 May 2018

Zeldis JB

7

1 reference

15 May 2018

language of work or name

English

0 references

publication date

1 December 1999

1 reference

15 May 2018

published in

Gastroenterology

1 reference

15 May 2018

volume

117

1 reference

15 May 2018

page(s)

1278-1287

1 reference

15 May 2018

issue

6

1 reference

15 May 2018

Inflammatory bowel disease

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970277-5

Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970277-5

Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970277-5

Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970277-5

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970277-5

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970277-5

Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970277-5

Infliximab for the treatment of fistulas in patients with Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970277-5

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970277-5

Treatment of severe colitis in Behçet's syndrome with thalidomide (CG-217)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970277-5

Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970277-5

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970277-5

Effect of IL-12 and antibodies to IL-12 on established granulomatous colitis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970277-5

Thalidomide in Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970277-5

Thalidomide in oral Crohn's disease refractory to conventional medical treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970277-5

Thalidomide for the treatment of oral aphthous ulcers in Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970277-5

Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970277-5

Thalidomide for the treatment of chronic graft-versus-host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970277-5

Thalidomide neuropathy: a clinical electrophysiological, and histological follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970277-5

Development of polyneuropathy during thalidomide therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970277-5

The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970277-5

Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970277-5

Thalidomide in human immunodeficiency virus (HIV) patients. A review of safety considerations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970277-5

Thalidomide neuropathy: an electrophysiologic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970277-5

Thalidomide hypersensitivity in AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970277-5

10.1016/S0016-5085(99)70277-5

7 January 2021

Identifiers

DOI

1 reference

15 May 2018

PubMed ID

10579968

1 reference

15 May 2018